An interventional study of Intranasal Oxytocin and Intranasal Arginine Vasopressin in Healthy, sponsored by University of Electronic Science and Technology of China. Recruiting at 1 site in China. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-28.
Sponsored by University of Electronic Science and Technology of China · Not applicable, Interventional, and Basic science
Explore the shared or separated neural mechanisms of social exclusion and social segregation and compare differential effects of AVP and OXT on these social interaction function.
A large body of research has shown that there are differences in the neural representation between social exclusion and social segregation, but the results are inconsistent, and the exploration of the neural basis is still insufficient. In addition, there are two mainstream theoretical explanations for these differences, namely the construction-level theory and the emotion-based theory, but there is no consistent theoretical model yet. Therefore, further exploration is necessary to confirm the cognitive and neural mechanisms underlying the differences between social exclusion and social segregation, and to attempt to reveal the theoretical explanations for these differences. In this project, the investigators propose to perform behavioral and functional magnetic resonance imaging (fMRI) techniques to examine the shared or separate neural mechanisms of social exclusion and social segregation (exp 1: social exclusion; exp 2: social separation) and investigate the modulatory effects of OXT/AVP on them (PLC/24IU OXT/20IU AVP).
University of Electronic Science and Technology of China is the lead sponsor of 109 studies on the registry; 35 are open to participants now.
Counted across the registry records on this site, refreshed daily.
EXclusion Criteria:
Administer oxytocin (24 IU) intranasally.
Drug: Intranasal Oxytocin
Administer Arginine Vasopressin (20 IU) intranasally.
Drug: Intranasal Arginine Vasopressin
Administer placebo intranasally.
Drug: Intranasal placebo
Control condition
Administer oxytocin (24 IU) intranasally, 6 individual 0.1 ml puffs (4 IU/0. 1ml), three puffs per nostril one every 30 seconds.
Administer arginine vasopressin (20 IU) intranasally, 6 individual 0.1 ml puffs (3.33 IU/0. 1ml), three puffs per nostril one every 30 seconds.
Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds.
Neural index: OXT and AVP effects on fMRI based- social exclusion and social separation tasks
Comparions between OXT and AVP on social exclusion and social separation on brain activity or representations
Time frame: 45 minutes after treatment administration
Behavioral index: behavioral ratings of social exclusion and social separation tasks
Comparions between social exclusion and social separation in pain ratings
Time frame: Immediately after fMRI scanning
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Electronic Science and Technology of China